Joel Picus

Joel Picus

UNVERIFIED PROFILE

Are you Joel Picus?   Register this Author

Register author
Joel Picus

Joel Picus

Publications by authors named "Joel Picus"

Are you Joel Picus?   Register this Author

75Publications

2125Reads

7Profile Views

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.

J Clin Oncol 2018 04 31;36(11):1080-1087. Epub 2018 Jan 31.

Christos E. Kyriakopoulos, Glenn Liu, and David F. Jarrard, University of Wisconsin (UW) School of Medicine and Public Health and UW Carbone Cancer Center, Madison, WI; Yu-Hui Chen and Christopher J. Sweeney, Dana-Farber Cancer Institute; Yu-Hui Chen, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group; Christopher J. Sweeney, Harvard Medical School, Boston, MA; Michael A. Carducci, Noah M. Hahn, and Mario Eisenberger, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD; Daniel H. Shevrin, NorthShore University HealthSystem, Evanston; Maha Hussain, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL; Robert Dreicer, University of Virginia Cancer Center, Charlottesville, VA; Manish Kohli, Mayo Clinic, Rochester, MN; Elizabeth R. Plimack, Fox Chase Cancer Center, Temple Health, Philadelphia, PA; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Joel Picus, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO; Matthew M. Cooney, Seidman Cancer Center, University Hospitals Cleveland Medical Center; Jorge A. Garcia, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; and Robert S. DiPaola, University of Kentucky College of Medicine, Lexington, KY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.3657DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891129PMC
April 2018

Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.

J Clin Oncol 2018 02 20;36(4):376-382. Epub 2017 Dec 20.

Lauren C. Harshman and Christopher J. Sweeney, Dana-Farber Cancer Institute, Harvard Medical School; Yu-Hui Chen, Dana-Farber Cancer Institute, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group, Boston, MA; Glenn Liu and David Jarrard, University of Wisconsin School of Medicine and Public Health and Carbone Cancer Center, Madison, WI; Michael A. Carducci, Noah Hahn, and Mario Eisenberger, Johns Hopkins University, Baltimore, MD; Robert Dreicer, University of Virginia Cancer Center, Charlottesville, VA; Jorge A. Garcia, Cleveland Clinic Taussig Cancer Institute; Matthew Cooney, University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland, OH; Maha Hussain, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago; Daniel Shevrin, NorthShore University Health System, Evanston, IL; Manish Kohli, Mayo Clinic, Rochester, MN; Elizabeth R. Plimack, Fox Chase Cancer Center, Temple Health, Philadelphia, PA; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Joel Picus, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO; and Robert Dipaola, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.75.3921
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.75.3921DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805480PMC
February 2018

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.

J Clin Oncol 2017 02 14;35(6):591-597. Epub 2016 Nov 14.

Toni K. Choueiri and Meghara K. Walsh, Dana-Farber Cancer Institute; M. Dror Michaelson, Massachusetts General Hospital Cancer Center, Boston, MA; Susan Halabi and Ben L. Sanford, Alliance Statistics and Data Center and Duke University; Daniel J. George, Duke Cancer Institute, Duke University Medical Center, Durham, NC; Olwen Hahn, Alliance Protocol Operations Office, Chicago, IL; Darren R. Feldman and Michael J. Morris, Memorial Sloan Kettering Cancer Center, New York, NY; Thomas Olencki, Ohio State University Medical Center, Columbus, OH; Joel Picus, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO; Eric J. Small, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; and Shaker Dakhil, University of Kansas Wichita, Wichita, KS.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.7398DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455807PMC
February 2017

Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study.

Support Care Cancer 2016 07 2;24(7):2837-42. Epub 2016 Feb 2.

Division of Hematology/Oncology, Melvin & Bren Simon Cancer Center, Indiana University School of Medicine, 535 Barnhill Drive, RT 400, Indianapolis, IN, 46202, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-016-3100-yDOI Listing
July 2016

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

N Engl J Med 2015 Aug 5;373(8):737-46. Epub 2015 Aug 5.

From the Department of Medicine (C.J.S.) and the Department of Biostatistics and Computational Biology (Y.-H.C.), Dana-Farber Cancer Institute, Boston; Harvard Medical School, Boston (C.J.S.); Johns Hopkins University, Baltimore (M.C., M.E.); University of Wisconsin Carbone Cancer Center (G.L., D.F.J.) and School of Medicine and Public Health (D.F.J.), Madison; Fox Chase Cancer Center, Temple University Health System, Philadelphia (Y.-N.W.); Indiana University Melvin and Bren Simon Cancer Center, Indianapolis (N.H.); Mayo Clinic, Rochester, MN (M.K.); University Hospitals Case Medical Center, Seidman Cancer Center (M.M.C.), and Cleveland Clinic Taussig Cancer Institute (J.A.G.) - both in Cleveland; University of Virginia Cancer Center, Charlottesville (R.D.); Comprehensive Cancer Centers of Nevada, Las Vegas (N.J.V.); Siteman Cancer Center, Washington University School of Medicine, St. Louis (J.P.); NorthShore University HealthSystem, Evanston, IL (D.S.); University of Michigan Comprehensive Cancer Center, Ann Arbor (M.H.); and Rutgers Cancer Institute of New Jersey, New Brunswick (R.S.D.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1503747DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562797PMC
August 2015

A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies.

Cancer Chemother Pharmacol 2014 Aug 11;74(2):419-26. Epub 2014 Jun 11.

Department of Medicine, Siteman Cancer Center, Washington University School of Medicine, 660 South Euclid Ave., Campus Box 8056, St. Louis, MO, 63110, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-014-2493-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4112045PMC
August 2014

Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma.

JOP 2012 Sep 10;13(5):497-501. Epub 2012 Sep 10.

Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO 63110, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6092/1590-8577/913DOI Listing
September 2012

Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75.

J Clin Oncol 2011 Apr 21;29(12):1525-30. Epub 2011 Mar 21.

Indiana University Melvin and Bren Simon Cancer Center, Indiana Cancer Pavilion Room RT445, 535 Barnhill Dr, Indianapolis, IN 46202, USA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2010.31.6067
Publisher Site
http://dx.doi.org/10.1200/JCO.2010.31.6067DOI Listing
April 2011

Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study.

HPB (Oxford) 2010 Aug;12(6):418-26

Division of Medical Oncology, Washington University School of Medicine, Saint Louis, MI 63110, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1477-2574.2010.00197.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3028583PMC
August 2010

Radiotherapy for epidermoid carcinoma of the anus: thirty years' experience.

Int J Radiat Oncol Biol Phys 2009 Oct 27;75(2):428-35. Epub 2009 Feb 27.

Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2008.11.047DOI Listing
October 2009

Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.

Pediatr Blood Cancer 2009 Jul;52(7):767-71

Pediatric Oncology, Dana-Farber Cancer Institute and Department of Medicine, Children's Hospital Boston, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.21909DOI Listing
July 2009

Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study.

Ann Surg 2008 Aug;248(2):145-51

Department of Surgery, Barnes-Jewish Hospital/Washington University Medical Center and Siteman Cancer Center, St Louis, Missouri 63110, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/SLA.0b013e318181e4e9DOI Listing
August 2008

A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer.

Cancer Chemother Pharmacol 2008 Mar 22;61(3):453-8. Epub 2007 May 22.

Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-007-0489-5
Publisher Site
http://dx.doi.org/10.1007/s00280-007-0489-5DOI Listing
March 2008

Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel.

Invest New Drugs 2007 Dec 7;25(6):565-70. Epub 2007 Jul 7.

Department of Medicine, Oregon Health & Science University Cancer Institute, Portland, OR 97239, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-007-9068-1DOI Listing
December 2007

Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors.

AJR Am J Roentgenol 2007 May;188(5):1201-7

Division of Interventional Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, 510 S Kingshighway Blvd., Box 8131, Saint Louis, MO 63110, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2214/AJR.06.0933DOI Listing
May 2007

A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008.

Cancer 2006 Sep;107(6):1273-9

Section of Hematology/Oncology, Department of Medicine, University of Chicago Medical Center, Chicago, Illinois 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.22117DOI Listing
September 2006

Phase II study of erlotinib in patients with advanced biliary cancer.

J Clin Oncol 2006 Jul;24(19):3069-74

Karmanos Cancer Institute, Wayne State University, 4-HWCRC, 4100 John R St, Detroit, MI 48201, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2005.05.3579DOI Listing
July 2006

The role of primary chemotherapy for prostate cancer: has the time come?

Curr Urol Rep 2006 May;7(3):233-8

Siteman Cancer Center, 660 South Euclid Avenue, Campus Box 8056, St. Louis, MO 63110, USA.

View Article

Download full-text PDF

Source
May 2006

Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.

J Clin Oncol 2005 Sep;23(27):6657-63

Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2005.14.696DOI Listing
September 2005

Evaluating risk factors for the development of ifosfamide encephalopathy.

Am J Clin Oncol 2005 Jun;28(3):277-80

Division of Medical Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri 63110, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.coc.0000158439.02724.5aDOI Listing
June 2005

Positron tomographic assessment of androgen receptors in prostatic carcinoma.

Eur J Nucl Med Mol Imaging 2005 Mar 22;32(3):344-50. Epub 2005 Feb 22.

The Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, 63110, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-005-1764-5DOI Listing
March 2005

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

J Clin Oncol 2004 Mar;22(6):1025-33

UCSF Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero St, Room A-718, San Francisco, CA 94115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2004.06.037DOI Listing
March 2004

Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group study.

Oncology 2003 ;65(3):218-23

Division of Hematology-Oncology, Indiana University Medical Center and Walther Cancer Institute, Indianapolis, IN 46202, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000074474DOI Listing
January 2004

Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.

J Clin Oncol 2003 Jul;21(14):2673-8

University of Massachusetts Memorial Health Center, Department of Oncology, 55 Lake Ave North, Worcester, MA 01655, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2003.11.102DOI Listing
July 2003

CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma.

Cancer Res 2003 May;63(9):2033-6

Departments of Surgery, Washington University School of Medicine, St. Louis, Missouri 63110, USA.

View Article

Download full-text PDF

Source
May 2003

11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse.

J Nucl Med 2003 Apr;44(4):549-55

Mallinckrodt Institute of Radiology, Washington University School of Medicine, 510 S. Kingshighway Boulevard, St. Louis, MO 63110, USA.

View Article

Download full-text PDF

Source
April 2003

Early results from a phase I/II radiation dose-escalation study with concurrent amifostine and infusional 5-fluorouracil chemotherapy for preoperative treatment of unresectable or locally recurrent rectal carcinoma.

Semin Oncol 2002 Dec;29(6 Suppl 19):29-33

Department of Radiation Oncology, and the Divisions of Colorectal Surgery and Medical Oncology, Washington University School of Medicine, St Louis, MO 63110-1001, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/sonc.2002.37360DOI Listing
December 2002

Severe interstitial pneumonitis associated with docetaxel administration.

Cancer 2002 Feb;94(3):847-53

Department of Medicine, Division of Medical Oncology at Washington University, St. Louis, Missouri, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.10263DOI Listing
February 2002